Last reviewed · How we verify
Golimumab Injection
Golimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Golimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Golimumab Injection |
|---|---|
| Also known as | Based on decision of investigators. |
| Sponsor | MSD Pharmaceuticals LLC |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TNF-α is a key pro-inflammatory cytokine that drives immune-mediated inflammation in autoimmune and inflammatory diseases. By neutralizing TNF-α, golimumab suppresses the inflammatory cascade and reduces disease activity. This mechanism is effective across multiple TNF-driven conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Ulcerative colitis
- Crohn's disease
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Nasopharyngitis
- Increased infection risk (serious infections)
- Tuberculosis reactivation
Key clinical trials
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (PHASE2)
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (PHASE2)
- Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (PHASE3)
- Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade (PHASE3)
- COVID-19 VaccinE Response in Rheumatology Patients (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Golimumab Injection CI brief — competitive landscape report
- Golimumab Injection updates RSS · CI watch RSS
- MSD Pharmaceuticals LLC portfolio CI